Emerging treatments
Your Organizational Guidance
ebpracticenet urges you to prioritize the following organizational guidance:
Obesitas bij kinderenPublished by: Domus Medica | SSMGLast published: 2008Obésité chez l'enfantPublished by: Domus Medica | SSMGLast published: 2008Amylin analogs
Amylin is a peptide that is cosecreted with insulin from the pancreatic beta cells and is thought to be important in the regulation of glucose and energy homeostasis. An analog of amylin is available for the treatment of diabetes mellitus in adults and is undergoing clinical trials for the treatment of adult obesity.[135][136]
Exendin 4
Exendin is an incretin mimetic undergoing clinical trials in adults with obesity. Exenatide, a synthetic version, is used for the treatment of type 2 diabetes mellitus in adults. It has been shown to decrease gastric emptying time and decrease food intake in clinical studies.[137] Initial trials in children have shown a reduction in body mass index (BMI) in children with severe obesity.[138][139]
Peptide YY(3-36)
Peptide YY is released by the gastrointestinal tract following a meal and acts by suppressing appetite. Clinical trials with a nasal formulation in adults did not meet the primary endpoints, and thus were stopped. Peptide YY is being studied as a potential therapy in patients who did not lose sufficient weight following bariatric surgery.[140]
Ghrelin antagonists
Ghrelin is a small peptide secreted from the stomach that is thought to be a signal for meal initiation. Thus, antagonism of ghrelin may be useful to suppress food intake.
Tirzepatide
Tirzepatide is a once-weekly dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.[141] It is approved for the treatment of type 2 diabetes mellitus and obesity in adults. Ongoing clinical trials are evaluating the safety and efficacy of tirzepatide for the treatment of obesity in adolescents age 12 years and older.
Use of this content is subject to our disclaimer